secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-08-01T23:59:59+00:00
Accession:  0001062822-24-000043
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted
-------------------------------------------------------------------------

- Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.
- INPEFA (sotagliflozin) net sales $1.6M; commercial launch ongoing.
- NDA for ZYNQUISTA in type 1 diabetes resubmitted; PDUFA goal date Dec 20, 2024.
- SONATA Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy commenced.
- PROGRESS Phase 2b (LX9211) for DPNP topline data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/0001062822-24-000043-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000043/lxrx-20240801.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000043

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer